Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30538454 | 1.00 | OPRM1 (0.43) | OPRM1OPRD1OPRK1PTGS1GSTK1 | |
| SCHEMBL30242086 | 0.98 | OPRM1 (0.40) | OPRM1OPRD1OPRK1PTGS1GSTK1 | |
| SCHEMBL30679580 | 0.85 | CALCR (0.44) | OPRM1OPRD1 | |
| SCHEMBL30538459 | 0.85 | CALCR (0.45) | OPRM1OPRD1CTSB | |
| SCHEMBL30679581 | 0.85 | CALCR (0.45) | OPRM1OPRD1CTSB | |
| SCHEMBL29965820 | 0.85 | CALCR (0.45) | OPRM1OPRD1CTSB | |
| SCHEMBL30974136 | 0.84 | OPRM1 (0.45) | OPRM1OPRD1OPRK1 | |
| SCHEMBL29783645 | 0.83 | MME (0.45) | — | |
| SCHEMBL30997370 | 0.83 | OPRM1 (0.48) | OPRM1OPRD1OPRK1 | |
| SCHEMBL30810334 | 0.81 | OPRM1 (0.43) | OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11926679-B2 | Oligopeptide search method, oligopeptide, modified peptide, and immunoassay method | ZEON CORPORATION (JP) | 2024-03-12 | — | — | US | claimed |
| US-12509489-B2 | Oligopeptide | ZEON CORPORATION (JP) | 2025-12-30 | — | — | US | disclosed |
| US-20240199694-A1 | OLIGOPEPTIDE | ZEON CORPORATION (JP) | 2024-06-20 | — | — | US | disclosed |
| US-11926679-B2 | Oligopeptide search method, oligopeptide, modified peptide, and immunoassay method | ZEON CORPORATION (JP) | 2024-03-12 | — | — | US | disclosed |
| US-20230047436-A1 | OLIGOPEPTIDE SEARCH METHOD, OLIGOPEPTIDE, MODIFIED PEPTIDE, AND IMMUNOASSAY METHOD | ZEON CORPORATION (JP) | 2023-02-16 | — | — | US | disclosed |
| US-11485757-B2 | Oligopeptide search method, oligopeptide, modified peptide, and immunoassay method | ZEON CORPORATION (JP) | 2022-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509489-B2 | Oligopeptide | FN1, HGF, TNFSF11 | OPRM1 996/4885OPRD1 725/4885OPRK1 1313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.